Answers are grounded in this paper and cite their sources.
Retrospective analysis evaluates efficacy of ipilimumab after anti-PD-1 failure in advanced melanoma, indicating treatment challenges.
INTRODUCTION: Currently, a substantial proportion of patients are still treated with first-line anti-PD-1 immunotherapy (ICI). After disease progression, treatment options, especially for patients with BRAF-negative tumors, are limited. One regimen used in real-world practice in this setting is ipilimumab monotherapy (anti-CTLA-4). This study aimed to assess the efficacy of ipilimumab monotherapy after progression on anti-PD-1 monotherapy. Moreover, the observed progression-free survival (PFS) and overall survival (OS) were compared with the efficacy of potential new drugs used in second-line treatment. MATERIAL AND METHODS: This retrospective analysis included patients who had received prior anti-PD-1 monotherapy and subsequently developed disease progression, after which ipilimumab was administered as second-line ICI. The primary outcome measures were objective response rate (ORR), PFS, and OS. Kaplan–Meier and Cox analyses were performed. RESULTS: A total of 120 patients were enrolled in the study. The ORR was 10.8%, with 1 (0.8%) patient achieving a complete response (CR) and 12 (10%) achieving a partial response (PR). Another 21 (17.5%) patients achieved stable disease (SD). In contrast, in85 (70.8%) patients had the best overall response of progressive disease (PD) to ipilimumab. The median PFS was 3 months (95% CI 2.6–3.7). At 6 months after the first dose, PFS was 29.9% (95% CI 22.7–39.5), and at 12 months it was 10.9% (95% CI 6.4–18.5). The median OS was 7.6 months (95% CI 6.2–10.1), with 1- and 2-year OS rates of 32.39% (95% CI 24.9–42.2) and 14.01% (95% CI 8.9–22), respectively. Male sex and increased lactate dehydrogenase (LDH) activity were significantly associated with worse PFS and OS. CONCLUSIONS: This study demonstrated that the real-world efficacy of ipilimumab monotherapy as second-line therapy in patients with advanced melanoma is similar to that reported in clinical trials. The observed ORR, PFS, and OS were relatively low; however, a small group of patients benefited from sequential anti-PD-1/anti-CTLA-4 therapy, raising the question of how to identify these patients upfront. The nivolumab-ipilimumab combination should be offered as a first-line treatment option in eligible patients.
No takes yet. Share an insight, caveat, or question.
Błoński et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: